ADMA Biologics

ADMA Biologics is one of the strangest profiles in healthcare mid-cap: a vertically integrated plasma derivatives manufacturer that first became GAAP-profitable in 2024, then delivered a quarter with operating margins above 30% in 2025 — and still crashed from 23 USD (Q3/2025 high) to 6.80 USD today. The stock sits at 7% of its 52-week range in Q2/2026.

The company has three core products: ASCENIV (RSV-titer hyperimmune IVIG for primary immunodeficiency, the growth driver up 50% YoY), BIVIGAM (standard IVIG), and Nabi-HB (hepatitis B hyperimmune). Plus a plasma collection subsidiary (ADMA BioCenters) with 11 sites — vertical integration that survived the 2021 pandemic plasma shortage and now structurally lifts gross margin (38% vs. industry average of 28%).

What triggered the drawdown: in the Q4/2025 call CEO Adam Grossman cut FY2026 revenue guidance by 8% to 475M USD on delayed ASCENIV pediatric approval. Plus: Takeda's BAX855 Vienna plant is back online after an 18-month maintenance period, returning the IVIG market from shortage to normal pricing. The market interpreted this as a structural margin collapse — possibly wrongly.

Smart-money concentration is modest but high quality: Perceptive Advisors holds 6.9% (one of their oldest healthcare long-term positions, since 2019), Tang Capital Partners 5.1%, Pinnacle Associates 4.3%. Notable: Perceptive did not trim into the Q1/2026 drawdown — rare constancy for a hedge fund after a -65% move.

Insider activity: this is the most interesting part of the story. CEO Adam Grossman bought 75,000 shares at 7.20 USD on the open market on March 14, 2026 — his largest open-market buy since the 2014 listing. CFO Brad Tade bought 25,000 shares at 7.40 USD. Board member James Mond (plasma industry veteran, former Grifols director) bought 40,000 shares at 7.15 USD. Three insider buys from top management after a -65% drawdown is a top-decile signal statistically — historical 12-month positive-return hit rate in healthcare mid-caps is 78%.

Short interest at 10.9% of float — high but declining since February 2026 (peak was 16.2%). Short-squeeze setup is in place if ASCENIV pediatric approval is confirmed.

ADMA is cheap on virtually every classical valuation metric: forward P/E 7.8×, EV/EBITDA 6.4×, EV/Sales 2.2× (vs. CSL Behring 4.1× and Grifols 3.3×). Sum-of-parts: BIVIGAM franchise (60M USD margin) at 8× EBIT = 480M USD; ASCENIV franchise (90M USD margin, growing) at 12× EBIT = 1.08B USD; BioCenters (vertical integration, 25M USD margin) at 10× = 250M USD; net cash 150M USD. Total around 2B USD or 14 USD per share — versus the current 6.80 USD this is 105% upside in a mid case. Consensus target 16.75 USD (median): H.C. Wainwright (22 USD, Buy), B. Riley (15 USD, Buy), Cantor Fitzgerald (13 USD, Buy). Not a single Hold or Sell rating.

1. Q2/2026 Earnings (August 2026): First demonstration of whether the Q1 FY2026 guidance cut was conservative — pricing-recovery data point for the IVIG market
2. Q3/2026 (September): FDA decision on ASCENIV pediatric label expansion — primary re-rating trigger
3. Q4/2026 (November): ADMA investor day in New York — plasma centers roadmap update and new hyperimmunes (pneumococcal, COVID-19 titer)

ADMA is exactly the type of beaten-up compounder I flag for high-conviction adds during watch-list reviews. Three insider buys after a -65% drawdown from insiders with industry expertise (Mond is a former Grifols director!) is no coincidence. The structural plasma vertical integration and ASCENIV growth remain intact — the bear thesis is cyclical (IVIG pricing), not structural. My approach: initial 2-3% portfolio position at 7-8 USD, add trigger on a Q2 earnings beat and/or ASCENIV pediatric approval, hard stop at 5.40 USD (the pre-IVIG-rally 2024 low). Asymmetry is clearly positive here: 25% downside risk versus 60-100% upside potential over 18 months.